Published in Int J Ophthalmol on October 18, 2013
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol (2009) 5.41
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22
Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology (2008) 3.90
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology (2005) 3.48
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol (2011) 2.49
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology (2009) 1.86
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67
Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology (2009) 1.52
Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol (2011) 1.28
Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology (2010) 1.23
Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol (2010) 1.09
Mechanisms for countering oxidative stress and damage in retinal pigment epithelium. Int Rev Cell Mol Biol (2012) 1.05
Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina (1995) 0.95
Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. Br J Ophthalmol (2011) 0.85
Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2010) 0.82
Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev (2008) 3.43
Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina (2007) 2.15
The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol (2008) 2.10
HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology (2012) 1.82
Discrepancy between fluorescein angiography and optical coherence tomography in detection of macular disease. Retina (2008) 1.78
Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology (2010) 1.64
The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol (2010) 1.63
Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina (2006) 1.61
Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol (2004) 1.57
Results of silicone oil removal in patients with cytomegalovirus retinitis related retinal detachments. Am J Ophthalmol (2005) 1.56
Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors: MuSIC Report II. Ophthalmology (2002) 1.52
Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. Ophthalmology (2007) 1.51
Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology (2011) 1.49
Choroidal volume variations with age, axial length, and sex in healthy subjects: a three-dimensional analysis. Ophthalmology (2012) 1.46
Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment. Retina (2012) 1.46
Visual outcomes after wavefront-guided laser in situ keratomileusis with and without iris registration. J Cataract Refract Surg (2008) 1.42
Endophthalmitis After Pars Plana Vitrectomy: Clinical Features, Risk Factors, and Management Outcomes. Asia Pac J Ophthalmol (Phila) (2016) 1.41
Correlation between morphologic features on spectral-domain optical coherence tomography and angiographic leakage patterns in macular edema. Retina (2010) 1.39
Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology (2011) 1.33
HIV-associated retinopathy in the HAART era. Retina (2005) 1.27
Optical coherence tomography-raster scanning and manual segmentation in determining drusen volume in age-related macular degeneration. Retina (2010) 1.26
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol (2012) 1.16
Avastin and new treatments for AMD: where are we? Retina (2006) 1.15
Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy. Am J Ophthalmol (2009) 1.13
Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci (2004) 1.12
Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch Ophthalmol (2011) 1.10
Repeatability and reproducibility of manual choroidal volume measurements using enhanced depth imaging optical coherence tomography. Invest Ophthalmol Vis Sci (2012) 1.10
Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci (2002) 1.10
Multifocal electroretinography in HIV-positive patients without infectious retinitis. Am J Ophthalmol (2008) 1.08
Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT. Am J Ophthalmol (2005) 1.08
Combined depth imaging technique on spectral-domain optical coherence tomography. Am J Ophthalmol (2012) 1.07
Correspondence. Retina (2015) 1.06
Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles. Biomaterials (2010) 1.05
Characterization of diabetic microaneurysms by simultaneous fluorescein angiography and spectral-domain optical coherence tomography. Am J Ophthalmol (2012) 1.05
Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci (2012) 1.04
The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm (2012) 1.03
Imaging of long-term retinal damage after resolved cotton wool spots. Ophthalmology (2009) 1.02
Scanning laser ophthalmoscope imaging stabilized microperimetry in dry age-related macular degeneration. Retina (2011) 1.02
Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol (2013) 1.02
Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci (2009) 1.01
Lidocaine gel anesthesia for intravitreal drug administration. Retina (2005) 1.01
Spectral domain optical coherence tomography for imaging ERM, retinal edema, and vitreomacular interface. Retina (2010) 1.00
Paradoxical activity of CMV retinitis in patients receiving highly active antiretroviral therapy. Retina (2002) 1.00
Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system. Invest Ophthalmol Vis Sci (2013) 0.99
Scleral buckle infections: microbiological spectrum and antimicrobial susceptibility. J Ophthalmic Inflamm Infect (2013) 0.97
Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am J Ophthalmol (2010) 0.97
Machine learning classifiers detect subtle field defects in eyes of HIV individuals. Trans Am Ophthalmol Soc (2007) 0.97
Focal navigated laser photocoagulation in retinovascular disease: clinical results in initial case series. Retina (2012) 0.96
SCLERAL BUCKLING WITH WIDE-ANGLED ENDOILLUMINATION AS A SURGICAL EDUCATIONAL TOOL. Retina (2016) 0.94
Combined depth imaging using optical coherence tomography as a novel imaging technique to visualize vitreoretinal choroidal structures. Retina (2013) 0.94
Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol (2003) 0.94
Prophylactic intraoperative 360 degrees laser retinopexy for prevention of retinal detachment. Retina (2007) 0.94
Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol (2010) 0.93
Hyperreflective sign in resolved cotton wool spots using high-resolution optical coherence tomography and optical coherence tomography ophthalmoscopy. Ophthalmology (2007) 0.93
A degenerative retinal process in HIV-associated non-infectious retinopathy. PLoS One (2013) 0.92
Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina (2012) 0.92
Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. Am J Ophthalmol (2013) 0.92
Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res (2008) 0.92